A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05767021 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis
Ulcerative Colitis Chronic

Interventions

DRUG: Mirikizumab
DRUG: Mirikizumab

Sponsor

Eli Lilly and Company